Page last updated: 2024-12-06

etoperidone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Etoperidone is an atypical antipsychotic medication that acts as a selective antagonist of dopamine D2 and serotonin 5-HT2A receptors. It is typically used to treat schizophrenia and other psychotic disorders. Its synthesis involves a multi-step process, starting with the coupling of 2-chloro-5-trifluoromethylpyridine with 4-bromobutyric acid. This reaction is followed by a series of steps including reduction, alkylation, and cyclization to form the final product. Etoperidone is thought to exert its therapeutic effects by blocking dopamine receptors in the brain, thereby reducing the symptoms of psychosis. Its importance lies in its efficacy and safety profile, as it has been shown to be effective in treating schizophrenia with a lower incidence of extrapyramidal side effects compared to typical antipsychotics. Research on etoperidone continues to explore its potential applications in other disorders such as bipolar disorder and obsessive-compulsive disorder.'

etoperidone: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID40589
CHEMBL ID1743259
CHEBI ID135589
SCHEMBL ID49314
MeSH IDM0061336

Synonyms (29)

Synonym
52942-31-1
2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-4,5-diethyl-2,4-dihydro-3h-1,2,4-triazol-3-one
etoperidone
PDSP1_000523
PDSP2_000521
CHEBI:135589
2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4,5-diethyl-1,2,4-triazol-3-one
L001188
CHEMBL1743259
bdbm82438
cas_52942-31-1
nsc_40589
1,2,4-triazol-3-one, 2-(3-(4-(3-chlorophenyl)-1-piperazinyl)propyl)-4,5-diethyl-2,4-dihydro-
etoperidonum
etoperidona
unii-kai6mvo39z
etoperidonum [inn-latin]
etoperidona [inn-spanish]
etoperidone [inn]
kai6mvo39z ,
etoperidona [spanish]
SCHEMBL49314
etoperidone [mi]
etoperidone [who-dd]
1-(3-(4-(m-chlorophenyl)-1-piperazinyl)propyl)-3,4-diethyl-d2-1,2,4-triazolin-5-one
IZBNNCFOBMGTQX-UHFFFAOYSA-N
DTXSID0023034
DB09194
Q5404839

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (52.63)18.7374
1990's6 (31.58)18.2507
2000's3 (15.79)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.71 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.76%)6.00%
Case Studies1 (4.76%)4.05%
Observational0 (0.00%)0.25%
Other19 (90.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]